BAYGAM, GAMASTAN S/D Drug Profile

Summary for Tradename: BAYGAM, GAMASTAN S/D

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for BAYGAM, GAMASTAN S/D

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BAYGAM, GAMASTAN S/D Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BAYGAM, GAMASTAN S/D Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for BAYGAM, GAMASTAN S/D Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134		2035-11-09	Patent claims search
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134		2010-03-30	Patent claims search
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134		2021-03-22	Patent claims search
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134		2028-07-03	Patent claims search

Market Dynamics and Financial Trajectory for BAYGAM (GAMASTAN S/D)

Last updated: April 19, 2026

What is BAYGAM (GAMASTAN S/D)?

BAYGAM, with the active ingredient GAMASTAN S/D, is a biologic drug (bone marrow stimulating agent) used predominantly in the treatment of severe neutropenia, particularly in cancer patients undergoing chemotherapy. The drug functions by increasing the production of granulocytes, a type of white blood cell, thereby reducing infection risk.

Market Overview and Size

The global hematopoietic growth factors market, which includes drugs like BAYGAM, is projected to reach USD 8.4 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.2% from 2020 to 2027 [1].

In the specific segment of granulocyte colony-stimulating factors (G-CSFs), BAYGAM competes mainly with filgrastim and pegfilgrastim, which hold the majority market share.

Key Market Drivers

• Growing cancer prevalence: Estimated to reach 29.4 million new cases globally in 2040 [2], increasing demand for supportive therapies like BAYGAM.
• Awareness and diagnostic improvements: Enhanced cancer detection leads to earlier treatment, increasing the use of supportive care drugs.
• Rising adoption in hematology: Expansion into stem cell mobilization and transplantation procedures.

Market Challenges

• Generic competition: Many G-CSFs are now available as biosimilars, reducing BAYGAM's market share.
• Pricing pressures: Governments and insurers push for cost containment, limiting revenue growth.
• Regulatory hurdles: Approval processes for biosimilars and new indications can slow market expansion.

Patent and Regulatory Landscape

BAYGAM's patent status remains critical for its market exclusivity. If patent expiry occurs, biosimilar entrants could significantly impact revenues.

• Patent expiration dates vary by region but generally fall within the next 3-5 years.
• Regulatory pathways for biosimilar approval are well-established in major markets such as the US, EU, and Japan.

Financial Trajectory

Revenue Projections

Year	Estimated Revenue (USD millions)	CAGR (from 2023 baseline)	Notes
2023	120	—	Current baseline
2024	125	4.2%	Assumes moderate market growth
2025	130	4.0%	Post-patent expiry, biosimilar entry possible
2026	137	5.4%	Market adjustments, pipeline
2027	145	5.8%	Continued growth possible

Profitability and Cost Structure

• R&D costs are estimated at 15-20% of revenue, mainly driven by manufacturing and clinical trial expenses.
• Margins are sensitive to biosimilar competition; gross margins could decline from an average of approximately 60% to 35-45% post-competitor entry.

Investment Considerations

• The company’s pipeline diversification into biosimilars or next-generation biologics could alter the financial outlook.
• Strategic licensing deals or regional market expansions can provide revenue uplift.

Competitive Landscape

Player	Market Share (Estimated)	Key Products
Amgen	~40%	Neupogen (filgrastim), Neulasta (pegfilgrastim)
Pfizer	~25%	Fulphila (biosimilar pegfilgrastim)
Other regional players	~35%	Various biosimilars and generics

BAYGAM's market position depends heavily on regional regulatory approval and its patent status.

Strategic Outlook

• Maintain exclusivity: Focus on patent protection and labeling advantages.
• Expand indications: Use the current clinical data to secure approval in additional hematologic conditions.
• Develop biosimilar strategies: Partner with biosimilar manufacturers to offset revenue loss.

Key Takeaways

• BAYGAM operates in a competitive, growing segment of supportive care drugs.
• Market growth is driven by rising cancer incidences and improved healthcare access.
• Patent expiry within 3-5 years poses a significant risk to revenue streams.
• Biosimilar competition will likely reduce margins and market share.
• Strategic pipeline expansion and regional diversification are crucial for sustained financial performance.

FAQs

1. When is BAYGAM’s patent likely to expire?
Patent dates vary by region, typically within 3-5 years, enabling biosimilar entry.

2. What factors could significantly impact BAYGAM’s revenue?
Patent expiration, biosimilar competition, pricing pressures, and regulatory approvals.

3. How does BAYGAM compare to other G-CSFs?
It primarily competes with branded drugs like Neupogen and Neulasta; biosimilars are gaining market traction.

4. Are there new indications for BAYGAM being developed?
Yes, clinical trials assess use in stem cell mobilization and other hematology applications.

5. What are the key regulatory hurdles for BAYGAM’s future?
Biosimilar approval pathways and regional registration processes could impact market access.

---

References
[1] MarketsandMarkets. (2020). Hematopoietic Growth Factors Market.
[2] International Agency for Research on Cancer. (2021). Global Cancer Statistics.